Cogent Biosciences (COGT) stock is in focus after the company released updated APEX trial data for bezuclastinib in advanced systemic mastocytosis, along with preclinical results for JAK2 V617F inhibitor CGT1145 at the 2026 EHA Congress.

The latest APEX and CGT1145 data arrive as Cogent Biosciences trades at US$33.67, with recent momentum reflected in a 7.3% 7 day share price return. The 1 year total shareholder return of about 4.7x highlights how sentiment has shifted over a longer horizon.

If this kind of trial driven move has your attention, it could be a good moment to see what else is setting up in healthcare, starting with 40 healthcare AI stocks

With Cogent Biosciences stock up strongly over the past year and recent trial headlines fresh in the price, the key question is whether current levels still leave upside on the table or if the market is already pricing in future growth.

Preferred Price to Book Multiple of 10.6x: Is it justified?

With Cogent Biosciences stock at $33.67, the current valuation lines up with a P/B ratio of 10.6x, which screens as expensive against peers yet cheaper than some close comparables.

The price to book multiple compares the market value of Cogent Biosciences to its net assets, which is a common yardstick for early stage biotechs that are still loss making. For a company with no reported revenue and a net loss of $354.303m, a higher P/B can reflect how much investors are willing to pay today for the pipeline of bezuclastinib and other programs.

On one side, Cogent Biosciences scores just 1 out of 6 on the internal value checks and the stock is described as expensive versus the wider US Biotechs industry average P/B of 2.4x. On the other side, it is described as good value when compared to a peer group average P/B of 26.1x, which points to investors assigning a mid range premium to its assets rather than the very top of the group.

Given that spread, the current 10.6x multiple signals the market is pricing Cogent Biosciences well above the sector as a whole, but at a discount to some closer peers that trade at much higher P/B levels.

Result: Price to book ratio of 10.6x (ABOUT RIGHT)

However, Cogent Biosciences still carries clear risks, including reliance on successful clinical outcomes for bezuclastinib and ongoing losses with no current revenue base.

Next Steps

Given the mix of optimism and caution around Cogent Biosciences, it makes sense to move quickly, review the full picture, and weigh both sides for yourself with 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Cogent Biosciences?

If Cogent Biosciences has caught your attention, do not stop here. Use this momentum to broaden your watchlist with other focused stock ideas.

• Target resilient cash generators that still look overlooked by the market with the 48 high quality undervalued stocks
• Strengthen your income stream by reviewing companies featured in the 8 dividend fortresses
• Prioritise sturdier business models and balance sheets by scanning the 65 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.